The State Medicaid Alternative Reimbursement and Purchasing Test for High-cost Drugs (SMART-D) initiative seeks to clarify the complicated state drug purchasing landscape and identify and test new drug payment options for states to consider. The work of SMART-D analyzes the options available to state Medicaid agencies to purchase and pay for high-cost specialty drugs under current federal law. The Center for Evidence-based Policy has sought to identify tools and techniques that states can use under current law to enable patient access to needed drugs while being an effective steward of scarce public dollars.
SMART-D Reports
Medicaid and Specialty Drugs: Current Policy Options – Policy Brief – June 2016
Medicaid Preferred Drug List Options for States – February 2020
SMART-D Tools for Multi-Agency Purchasing and PDL Options – January 2021